Symbols / ARVN Stock $9.65 +0.84% Arvinas, Inc.

Healthcare • Biotechnology • United States • NMS
ARVN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Randy Teel Ph.D.
Exch · Country NMS · United States
Market Cap 622.59M
Enterprise Value 10.97M
Income -221.30M
Sales 89.40M
FCF (ttm) -199.64M
Book/sh 6.00
Cash/sh 9.53
Employees 246
Insider 10d —
IPO Sep 27, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.84
PEG —
P/S 6.96
P/B 1.61
P/C —
EV/EBITDA -0.04
EV/Sales 0.12
Quick Ratio 5.36
Current Ratio 5.44
Debt/Eq 2.17
LT Debt/Eq —
EPS (ttm) -3.18
EPS next Y -3.40
EPS Growth —
Revenue Growth -91.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-11
ROA -18.92%
ROE -42.28%
ROIC —
Gross Margin 134.45%
Oper. Margin -4.05%
Profit Margin -247.54%
Shs Outstand 64.52M
Shs Float 55.89M
Insider Own 7.83%
Instit Own 84.90%
Short Float 8.00%
Short Ratio 5.75
Short Interest 4.42M
52W High 14.51
vs 52W High -33.49%
52W Low 5.90
vs 52W Low 63.56%
Beta 1.80
Impl. Vol. 41.58%
Rel Volume 0.24
Avg Volume 900.94K
Volume 214.38K
Target (mean) $15.40
Tgt Median $16.00
Tgt Low $6.00
Tgt High $24.00
# Analysts 15
Recom Buy
Prev Close $9.57
Price $9.65
Change 0.84%
About

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.40
Mean price target
2. Current target
$9.65
Latest analyst target
3. DCF / Fair value
$-55.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.65
Low
$6.00
High
$24.00
Mean
$15.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-13 main Barclays Overweight → Overweight $20
2026-05-13 main BTIG Buy → Buy $18
2026-05-04 main Citigroup Buy → Buy $24
2026-03-19 main Citigroup Buy → Buy $21
2026-03-19 main BTIG Buy → Buy $16
2026-03-05 main Citigroup Buy → Buy $18
2026-02-25 reit Piper Sandler Overweight → Overweight $20
2026-02-25 main Evercore ISI Group Outperform → Outperform $19
2026-02-25 main Wedbush Neutral → Neutral $11
2026-01-06 up Citigroup Neutral → Buy $15
2025-12-17 main Barclays Overweight → Overweight $18
2025-11-10 main Stephens & Co. Overweight → Overweight $15
2025-11-06 main Wells Fargo Overweight → Overweight $15
2025-11-06 main Barclays Overweight → Overweight $16
2025-10-30 main BTIG Buy → Buy $14
2025-10-15 down Goldman Sachs Neutral → Sell $6
2025-09-18 main BTIG Buy → Buy $10
2025-09-18 main Stephens & Co. Overweight → Overweight $14
2025-08-07 main HC Wainwright & Co. Buy → Buy $18
2025-08-07 main Wells Fargo Overweight → Overweight $16
News
RSS: Latest ARVN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-18 BERKOWITZ NOAH Officer — 6,435 $11.10 $71,431
2026-03-06 MORRISON BRIGGS W. M.D. Director — 20,000 $13.40 $268,070
2026-02-27 HOUSTON JOHN G Director — 35,297 $13.14 $466,154
2026-02-26 BERKOWITZ NOAH Officer — 45,000 $0.00 $0
2026-02-26 SAIK ANDREW Chief Financial Officer — 45,000 $0.00 $0
2026-02-26 LOOMIS DAVID K Officer — 12,420 $0.00 $0
2026-02-26 TEEL RANDY PH.D. Chief Executive Officer — 147,791 $0.00 $0
2026-02-26 TEEL RANDY PH.D. Chief Executive Officer — 147,179 $0.00 $0
2026-02-26 CACACE ANGELA M Officer — 45,000 $0.00 $0
2026-02-23 LOOMIS DAVID K Officer — 1,108 $12.16 $13,473
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
262.60
-0.30%
263.40
+235.54%
78.50
-40.26%
131.40
Operating Revenue
262.60
-0.30%
263.40
+235.54%
78.50
-40.26%
131.40
Operating Expense
381.10
-25.80%
513.60
+7.00%
480.00
+21.64%
394.60
Research And Development
285.20
-18.09%
348.20
-8.30%
379.70
+20.54%
315.00
Selling General And Administration
95.90
-42.02%
165.40
+64.91%
100.30
+26.01%
79.60
General And Administrative Expense
95.90
-42.02%
165.40
+64.91%
100.30
+26.01%
79.60
Other Gand A
95.90
-42.02%
165.40
+64.91%
100.30
+26.01%
79.60
Total Expenses
381.10
-25.80%
513.60
+7.00%
480.00
+21.64%
394.60
Operating Income
-118.50
+52.64%
-250.20
+37.68%
-401.50
-52.55%
-263.20
Total Operating Income As Reported
-118.50
+52.64%
-250.20
+37.68%
-401.50
-52.55%
-263.20
EBITDA
-113.30
+53.49%
-243.60
+38.30%
-394.80
-54.82%
-255.00
Normalized EBITDA
-113.30
+53.49%
-243.60
+38.30%
-394.80
-54.82%
-255.00
Reconciled Depreciation
5.20
-21.21%
6.60
-1.49%
6.70
-18.29%
8.20
EBIT
-118.50
+52.64%
-250.20
+37.68%
-401.50
-52.55%
-263.20
Net Income
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Pretax Income
-80.50
+59.40%
-198.30
+45.51%
-363.90
-44.98%
-251.00
Net Non Operating Interest Income Expense
38.40
-29.93%
54.80
+41.24%
38.80
+223.33%
12.00
Interest Expense Non Operating
—
—
—
—
Net Interest Income
38.40
-29.93%
54.80
+41.24%
38.80
+223.33%
12.00
Interest Expense
—
—
—
—
Interest Income Non Operating
38.40
-29.93%
54.80
+41.24%
38.80
+223.33%
12.00
Interest Income
38.40
-29.93%
54.80
+41.24%
38.80
+223.33%
12.00
Other Income Expense
-0.40
+86.21%
-2.90
-141.67%
-1.20
-700.00%
0.20
Other Non Operating Income Expenses
-0.40
+86.21%
-2.90
-141.67%
-1.20
-700.00%
0.20
Tax Provision
0.30
-50.00%
0.60
-33.33%
0.90
-95.69%
20.90
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Net Income From Continuing Operation Net Minority Interest
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Net Income From Continuing And Discontinued Operation
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Net Income Continuous Operations
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Normalized Income
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Net Income Common Stockholders
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Diluted EPS
—
-2.77
+58.16%
-6.62
-24.67%
-5.31
Basic EPS
—
-2.77
+58.16%
-6.62
-24.67%
-5.31
Basic Average Shares
—
71.90
+29.55%
55.50
+4.32%
53.20
Diluted Average Shares
—
71.90
+29.55%
55.50
+4.32%
53.20
Diluted NI Availto Com Stockholders
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Earnings From Equity Interest
—
—
—
—
Earnings From Equity Interest Net Of Tax
0.00
0.00
+100.00%
-2.50
+76.42%
-10.60
Line Item Trend 2025-12-31 2023-12-31
Total Assets
717.90
-44.97%
1,304.60
Current Assets
700.70
-45.27%
1,280.20
Cash Cash Equivalents And Short Term Investments
685.40
-45.65%
1,261.00
Cash And Cash Equivalents
142.90
-54.15%
311.70
Other Short Term Investments
542.50
-42.85%
949.30
Receivables
6.40
-11.11%
7.20
Accounts Receivable
1.00
0.00
Other Receivables
5.40
-25.00%
7.20
Prepaid Assets
—
—
Restricted Cash
—
5.50
Other Current Assets
8.90
+36.92%
6.50
Total Non Current Assets
17.20
-29.51%
24.40
Net PPE
13.40
-4.29%
14.00
Gross PPE
41.60
+18.52%
35.10
Accumulated Depreciation
-28.20
-33.65%
-21.10
Properties
0.00
0.00
Machinery Furniture Equipment
3.00
+15.38%
2.60
Other Properties
29.50
+40.48%
21.00
Leases
9.10
-20.87%
11.50
Non Current Accounts Receivable
—
—
Other Non Current Assets
3.80
-63.46%
10.40
Total Liabilities Net Minority Interest
284.10
-55.93%
644.60
Current Liabilities
142.50
-44.57%
257.10
Payables And Accrued Expenses
52.00
-21.80%
66.50
Payables
29.20
+57.84%
18.50
Accounts Payable
24.40
+37.08%
17.80
Current Accrued Expenses
22.80
-52.50%
48.00
Pensionand Other Post Retirement Benefit Plans Current
17.50
-31.91%
25.70
Total Tax Payable
4.80
+585.71%
0.70
Income Tax Payable
4.80
+585.71%
0.70
Current Debt And Capital Lease Obligation
1.70
-10.53%
1.90
Current Capital Lease Obligation
1.70
-10.53%
1.90
Current Deferred Liabilities
71.30
-56.26%
163.00
Current Deferred Revenue
71.30
-56.26%
163.00
Total Non Current Liabilities Net Minority Interest
141.60
-63.46%
387.50
Long Term Debt And Capital Lease Obligation
7.20
+453.85%
1.30
Long Term Debt
0.40
-50.00%
0.80
Long Term Capital Lease Obligation
6.80
+1260.00%
0.50
Non Current Deferred Liabilities
134.30
-65.23%
386.20
Non Current Deferred Revenue
134.30
-65.23%
386.20
Other Non Current Liabilities
0.10
—
Stockholders Equity
433.80
-34.27%
660.00
Common Stock Equity
433.80
-34.27%
660.00
Capital Stock
0.00
-100.00%
0.10
Common Stock
0.00
-100.00%
0.10
Preferred Stock
0.00
0.00
Share Issued
73.50
+8.09%
68.00
Ordinary Shares Number
63.50
-6.62%
68.00
Treasury Shares Number
10.00
0.00
Additional Paid In Capital
2,136.90
+7.08%
1,995.70
Retained Earnings
-1,612.40
-20.99%
-1,332.70
Gains Losses Not Affecting Retained Earnings
1.20
+138.71%
-3.10
Treasury Stock
91.90
—
Other Equity Adjustments
1.20
+138.71%
-3.10
Total Equity Gross Minority Interest
433.80
-34.27%
660.00
Total Capitalization
434.20
-34.29%
660.80
Working Capital
558.20
-45.44%
1,023.10
Invested Capital
434.20
-34.29%
660.80
Total Debt
8.90
+178.13%
3.20
Capital Lease Obligations
8.50
+254.17%
2.40
Net Tangible Assets
433.80
-34.27%
660.00
Tangible Book Value
433.80
-34.27%
660.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-273.80
-5.59%
-259.30
+25.45%
-347.80
-27.17%
-273.50
Cash Flow From Continuing Operating Activities
-273.80
-5.59%
-259.30
+25.45%
-347.80
-27.17%
-273.50
Net Income From Continuing Operations
-80.80
+59.38%
-198.90
+45.85%
-367.30
-30.02%
-282.50
Depreciation Amortization Depletion
5.20
-21.21%
6.60
-1.49%
6.70
-18.29%
8.20
Depreciation
5.20
-21.21%
6.60
-1.49%
6.70
-18.29%
8.20
Depreciation And Amortization
5.20
-21.21%
6.60
-1.49%
6.70
-18.29%
8.20
Other Non Cash Items
-8.50
+50.58%
-17.20
-12.42%
-15.30
-304.00%
7.50
Stock Based Compensation
44.00
-50.11%
88.20
+23.18%
71.60
-5.17%
75.50
Operating Gains Losses
—
2.60
+188.89%
0.90
+125.00%
0.40
Gain Loss On Investment Securities
—
—
0.90
+125.00%
0.40
Gain Loss On Sale Of PPE
0.00
-100.00%
2.60
0.00
0.00
Change In Working Capital
-233.70
-66.22%
-140.60
-216.67%
-44.40
+46.25%
-82.60
Change In Receivables
7.30
+176.84%
-9.50
-1287.50%
0.80
-95.48%
17.70
Changes In Account Receivables
4.70
+182.46%
-5.70
-670.00%
1.00
-92.86%
14.00
Change In Prepaid Assets
5.30
+175.71%
-7.00
-149.65%
14.10
+883.33%
-1.80
Change In Payables And Accrued Expense
-1.70
+91.98%
-21.20
-222.54%
17.30
-14.36%
20.20
Change In Accrued Expense
—
—
—
—
Change In Payable
-1.70
+91.98%
-21.20
-222.54%
17.30
-14.36%
20.20
Change In Account Payable
-1.70
+91.98%
-21.20
-222.54%
17.30
-14.36%
20.20
Change In Other Working Capital
-242.60
-140.20%
-101.00
-35.39%
-74.60
+36.13%
-116.80
Change In Other Current Liabilities
-2.00
-5.26%
-1.90
+5.00%
-2.00
-5.26%
-1.90
Investing Cash Flow
407.60
+1074.64%
34.70
-82.95%
203.50
-16.19%
242.80
Cash Flow From Continuing Investing Activities
407.60
+1074.64%
34.70
-82.95%
203.50
-16.19%
242.80
Net PPE Purchase And Sale
-1.90
-11.76%
-1.70
+41.38%
-2.90
+57.35%
-6.80
Purchase Of PPE
-1.90
-5.56%
-1.80
+37.93%
-2.90
+57.35%
-6.80
Sale Of PPE
0.00
-100.00%
0.10
0.00
0.00
Capital Expenditure
-1.90
-5.56%
-1.80
+37.93%
-2.90
+57.35%
-6.80
Net Investment Purchase And Sale
409.50
+1025.00%
36.40
-82.36%
206.40
-17.31%
249.60
Purchase Of Investment
-354.20
+45.68%
-652.10
+31.81%
-956.30
-7.89%
-886.40
Sale Of Investment
763.70
+10.92%
688.50
-40.78%
1,162.70
+2.35%
1,136.00
Financing Cash Flow
-91.40
-1256.96%
7.90
-97.89%
374.70
+7872.34%
4.70
Cash Flow From Continuing Financing Activities
-91.40
-1256.96%
7.90
-97.89%
374.70
+7872.34%
4.70
Net Issuance Payments Of Debt
-0.20
+50.00%
-0.40
0.00
0.00
Repayment Of Debt
-0.20
+50.00%
-0.40
0.00
0.00
Long Term Debt Payments
-0.20
+50.00%
-0.40
0.00
0.00
Net Long Term Debt Issuance
-0.20
+50.00%
-0.40
0.00
0.00
Net Common Stock Issuance
-91.90
0.00
-100.00%
387.20
0.00
Common Stock Payments
-91.90
0.00
0.00
—
Repurchase Of Capital Stock
-91.90
0.00
0.00
—
Proceeds From Stock Option Exercised
0.70
-91.57%
8.30
+84.44%
4.50
-4.26%
4.70
Net Other Financing Charges
—
—
-17.00
—
Changes In Cash
42.40
+119.57%
-216.70
-194.05%
230.40
+986.15%
-26.00
Beginning Cash Position
100.50
-68.32%
317.20
+265.44%
86.80
-23.05%
112.80
End Cash Position
142.90
+42.19%
100.50
-68.32%
317.20
+265.44%
86.80
Free Cash Flow
-275.70
-5.59%
-261.10
+25.55%
-350.70
-25.12%
-280.30
Interest Paid Supplemental Data
—
—
0.00
0.00
Income Tax Paid Supplemental Data
—
2.30
-79.28%
11.10
+0.00%
11.10
Common Stock Issuance
0.00
0.00
-100.00%
387.20
0.00
Issuance Of Capital Stock
0.00
0.00
-100.00%
387.20
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category